RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells) The long view is eventually moving pelareorep into first line therapy in combination with a variation of immune checkpoint inhibitors +/- bispecifics +/- ADCs +/- small molecule inhibitors. +/- CAR-T therapy., for example.